Literature DB >> 17255278

Cumulative incidence in competing risks data and competing risks regression analysis.

Haesook T Kim1.   

Abstract

Competing risks occur commonly in medical research. For example, both treatment-related mortality and disease recurrence are important outcomes of interest and well-known competing risks in cancer research. In the analysis of competing risks data, methods of standard survival analysis such as the Kaplan-Meier method for estimation of cumulative incidence, the log-rank test for comparison of cumulative incidence curves, and the standard Cox model for the assessment of covariates lead to incorrect and biased results. In this article, we discuss competing risks data analysis which includes methods to calculate the cumulative incidence of an event of interest in the presence of competing risks, to compare cumulative incidence curves in the presence of competing risks, and to perform competing risks regression analysis. A hypothetical numeric example and real data are used to compare those three methods in the competing risks data analysis to their respective counterparts in the standard survival analysis. The source and magnitude of bias from the Kaplan-Meier estimate is also detailed.

Entities:  

Mesh:

Year:  2007        PMID: 17255278     DOI: 10.1158/1078-0432.CCR-06-1210

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  152 in total

1.  The use and interpretation of competing risks regression models.

Authors:  James J Dignam; Qiang Zhang; Masha Kocherginsky
Journal:  Clin Cancer Res       Date:  2012-01-26       Impact factor: 12.531

2.  Total Femur Replacement After Tumor Resection: Limb Salvage Usually Achieved But Complications and Failures are Common.

Authors:  Florian Sevelda; Reinhard Schuh; Jochen Gerhard Hofstaetter; Martina Schinhan; Reinhard Windhager; Philipp Theodor Funovics
Journal:  Clin Orthop Relat Res       Date:  2015-04-02       Impact factor: 4.176

Review 3.  Sensitivity analysis using elicited expert information for inference with coarsened data: illustration of censored discrete event times in the AIDS Link to Intravenous Experience (ALIVE) Study.

Authors:  Michelle Shardell; Daniel O Scharfstein; David Vlahov; Noya Galai
Journal:  Am J Epidemiol       Date:  2008-10-24       Impact factor: 4.897

4.  Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?

Authors:  James F Troendle; Eric S Leifer; Lauren Kunz
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

5.  Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.

Authors:  Selin Tokez; Marlies Wakkee; Marieke Louwman; Eline Noels; Tamar Nijsten; Loes Hollestein
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

6.  Competing risk of death: an important consideration in studies of older adults.

Authors:  Sarah D Berry; Long Ngo; Elizabeth J Samelson; Douglas P Kiel
Journal:  J Am Geriatr Soc       Date:  2010-03-22       Impact factor: 5.562

7.  Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.

Authors:  Amir A Toor; Roy T Sabo; Catherine H Roberts; Bonny L Moore; Salman R Salman; Allison F Scalora; May T Aziz; Ali S Shubar Ali; Charles E Hall; Jeremy Meier; Radhika M Thorn; Elaine Wang; Shiyu Song; Kristin Miller; Kathryn Rizzo; William B Clark; John M McCarty; Harold M Chung; Masoud H Manjili; Michael C Neale
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

8.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

9.  Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

Authors:  Michael Gnant; Jose Baselga; Hope S Rugo; Shinzaburo Noguchi; Howard A Burris; Martine Piccart; Gabriel N Hortobagyi; Janice Eakle; Hirofumi Mukai; Hiroji Iwata; Matthias Geberth; Lowell L Hart; Peyman Hadji; Mona El-Hashimy; Shantha Rao; Tetiana Taran; Tarek Sahmoud; David Lebwohl; Mario Campone; Kathleen I Pritchard
Journal:  J Natl Cancer Inst       Date:  2013-02-19       Impact factor: 13.506

10.  Prediction of graft patency and mortality after distal revascularization and interval ligation for hemodialysis access-related hand ischemia.

Authors:  Salvatore T Scali; Catherine K Chang; Dan Raghinaru; Michael J Daniels; Adam W Beck; Robert J Feezor; Scott A Berceli; Thomas S Huber
Journal:  J Vasc Surg       Date:  2012-12-12       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.